Abstract
No clinical isolates have been reported for the recently described thermoactinomycete Kroppenstedtia eburnea. Between 2006 and 2011, we obtained 14 clinical isolates from patients in 9 U.S. states. Here we report growth characteristics, 16S rRNA gene sequencing, matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry-based identification, and antimicrobial susceptibility profiles of this recently described organism.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Anti-Bacterial Agents / pharmacology
-
Bacillales / chemistry
-
Bacillales / genetics
-
Bacillales / growth & development
-
Bacillales / isolation & purification*
-
Cluster Analysis
-
DNA, Bacterial / chemistry
-
DNA, Bacterial / genetics
-
DNA, Ribosomal / chemistry
-
DNA, Ribosomal / genetics
-
Female
-
Gram-Positive Bacterial Infections / microbiology*
-
Humans
-
Infant
-
Male
-
Microbial Sensitivity Tests
-
Middle Aged
-
Phylogeny
-
RNA, Ribosomal, 16S / genetics
-
Sequence Analysis, DNA
-
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
-
United States
Substances
-
Anti-Bacterial Agents
-
DNA, Bacterial
-
DNA, Ribosomal
-
RNA, Ribosomal, 16S